Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye

Exclusion Criteria

• •Have participated in a previous tavilermide (MIM-D3) study;
• •Have clinically significant slit lamp findings at Visit 1;
• •Have a history of lacrimal duct obstruction within 12 months of Visit 1;
• •Have an uncontrolled systemic disease;
• •Be a woman who is pregnant, nursing or planning a pregnancy;
• •Be a woman of childbearing potential who is not using an acceptable means of birth control;
• •Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study;
• •Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days prior to Visit 1.